miR-448 targets IDO1 and regulates CD8+ T cell response in human colon cancer

Lou, Qiong; Liu, Ruixian; Yang, Xiangling; Li, Weiqian; Huang, Likun; Wei, Lili; Tan, Huiliu; Xiang, Nanlin; Chan, Ka-Wo; Chen, Junxiong; Liu, Huanliang

doi:10.1186/s40425-019-0691-0

Cited by 87 publications

(75 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, Lou et al found that miR-448 acted as a tumor suppressive factor by targeting downstream IDO1 in colon cancer cells. The results of in vitro study showed that the ectopic expression of miR-448 was beneficial to giving full play to the functions of TILs [124]. Moreover, Huang et al reported that miR-153 level was a core factor determining the efficacy of chimeric antigen receptor (CAR) T cells treatment in colon cancer models.…”

Section: Cancer Cell Metabolite-related Mirnasmentioning

confidence: 99%

The role of cancer-derived microRNAs in cancer immune escape

et al. 2020

View full text Add to dashboard Cite

During malignant transformation, accumulated somatic mutations endow cancer cells with increased invasiveness and immunogenicity. Under selective pressure, these highly immunogenic cancer cells develop multiple strategies to evade immune attack. It has been well established that cancer cells could downregulate the expression of major histocompatibility complex, acquire alterations in interferon pathway, and upregulate the activities of immune checkpoint pathways. Besides, cancer cells secret numerous cytokines, exosomes, and microvesicles to regulate the functions and abundances of components in the tumor microenvironment including immune effector cells and professional antigen presentation cells. As the vital determinant of post-transcriptional regulation, microRNAs (miRNAs) not only participate in cancer initiation and progression but also regulate anti-cancer immune response. For instance, some miRNAs affect cancer immune surveillance and immune escape by interfering the expression of immune attack-associated molecules. A growing body of evidence indicated that cancer-derived immune modulatory miRNAs might be promising targets to counteract cancer immune escape. In this review, we summarized the role of some miRNAs in cancer immune escape and discussed their potential clinical application as treatment targets.

show abstract

Section: Cancer Cell Metabolite-related Mirnasmentioning

confidence: 99%

The role of cancer-derived microRNAs in cancer immune escape

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Their deregulation in the TME following the development of the disease must be elucidated for their direct impact not only on the proliferation of malignant cells but also on immune TME cells. Interestingly, it was reported that in human colon cancer, miR-448 could suppress CD8+ T-cell apoptosis and enhance the CD8+ T-cell response by inhibiting indoleamine 2,3-dioxygenase 1 enzyme function [ 28 ]. In our results, we also observed other differentially expressed miRNAs, including miR-520a, 651, 520f and 449, that were upregulated in patients and undetectable or expressed at very low levels in HD.…”

Section: Discussionmentioning

confidence: 99%

Identification of Acute Myeloid Leukemia Bone Marrow Circulating MicroRNAs

Agha

Rouas

Najar

et al. 2020

IJMS

View full text Add to dashboard Cite

Background: In addition to their roles in different biological processes, microRNAs in the tumor microenvironment appear to be potential diagnostic and prognostic biomarkers for various malignant diseases, including acute myeloid leukemia (AML). To date, no screening of circulating miRNAs has been carried out in the bone marrow compartment of AML. Accordingly, we investigated the circulating miRNA profile in AML bone marrow at diagnosis (AMLD) and first complete remission post treatment (AMLPT) in comparison to healthy donors (HD). Methods: Circulating miRNAs were isolated from AML bone marrow aspirations, and a low-density TaqMan miRNA array was performed to identify deregulated miRNAs followed by quantitative RT-PCR to validate the results. Bioinformatic analysis was conducted to evaluate the diagnostic and prognostic accuracy of the highly and significantly identified deregulated miRNA(s) as potential candidate biomarker(s). Results: We found several deregulated miRNAs between the AMLD vs. HD vs. AMLPT groups, which were involved in tumor progression and immune suppression pathways. We also identified significant diagnostic and prognostic signatures with the ability to predict AML patient treatment response. Conclusions: This study provides a possible role of enriched circulating bone marrow miRNAs in the initiation and progression of AML and highlights new markers for prognosis and treatment monitoring.

show abstract

“…To this end, elevated expression of indoleamine 2,3-dioxygenase 1 (IDO1), an enzyme which metabolizes tryptophan into kynurenine, in the TME has been shown todrive the differentiation of several immunosuppressive cell types [19], including Treg cells [20][21][22], immunosuppressive dendritic cells [23,24] and macrophages [25,26], or to directly suppress anti-tumor immunity [27]. In colorectal cancer, overexpression of IDO1 suppressed the CD8 T cell responses, leading to enhanced tumor growth [27]. In this study, miR-448 was shown to be able to enhance the survival of CD8 T cells by directly attenuating the upregulation of IDO1 in colorectal tumor cells in response to IFNγ stimulation.…”

Section: Immunometabolites Regulated By Mirnasmentioning

confidence: 99%

“…In this study, miR-448 was shown to be able to enhance the survival of CD8 T cells by directly attenuating the upregulation of IDO1 in colorectal tumor cells in response to IFNγ stimulation. Similarly, miR-153 has also been shown to target IDO1 in colorectal cancer in response to IFNγ [27,28]. Moreover, when combining miR-153-mediated IDO1 inhibition and chimeric antigen receptor (CAR) T cell therapy, further enhanced in vitro T cell killing activities and reduced xenograft tumor growth in mice were reported [27,28].…”

Section: Immunometabolites Regulated By Mirnasmentioning

confidence: 99%

MicroRNAs and Their Targetomes in Tumor-Immune Communication

Cho

Tai

2020

Cancers

View full text Add to dashboard Cite

The development of cancer is a complex and dynamically regulated multiple-step process that involves many changes in gene expression. Over the last decade, microRNAs (miRNAs), a class of short regulatory non-coding RNAs, have emerged as key molecular effectors and regulators of tumorigenesis. While aberrant expression of miRNAs or dysregulated miRNA-mediated gene regulation in tumor cells have been shown to be capable of directly promoting or inhibiting tumorigenesis, considering the well-reported role of the immune system in cancer, tumor-derived miRNAs could also impact tumor growth through regulating anti-tumor immune responses. Here, we discuss howmiRNAs can function as central mediators that influence the crosstalk between cancer and the immune system. Moreover, we also review the current progress in the development of novel experimental approaches for miRNA target identification that will facilitate our understanding of miRNA-mediated gene regulation in not only human malignancies, but also in other genetic disorders.

show abstract

miR-448 targets IDO1 and regulates CD8+ T cell response in human colon cancer

Cited by 87 publications

References 46 publications

The role of cancer-derived microRNAs in cancer immune escape

The role of cancer-derived microRNAs in cancer immune escape

Identification of Acute Myeloid Leukemia Bone Marrow Circulating MicroRNAs

MicroRNAs and Their Targetomes in Tumor-Immune Communication

Contact Info

Product

Resources

About